Vaccines

(328) A Comprehensive Review and Meta-analysis of COVID-19 Vaccine Studies in Vulnerable Populations- Analysis of 126 observational and clinical trials up to November 2022

(329) A Population Database Analysis To Estimate The Varicella Vaccine Effectiveness In Children <14 Years In A High Vaccination Coverage Area From 2004 To 2022

(330) A Comparison of Natural Language Processing (NLP) vs Clinician Review for Identification of Myocarditis Cases Following Vaccination with mRNA-1273

(330) A population-based observational study of determinants of varicella vaccination in the private market in Denmark

(331) Active Safety Monitoring of COVID-19 Vaccines in France using Patient-Reported Outcomes

(331) Applicability of Selected Brighton Collaboration Case Definitions in Prospective Hospital-Based Safety Surveillance for Covid-19 Vaccines, Addis Ababa, Ethiopia

(332) Associations Between the Latest Received Dose of mRNA COVID-19 Vaccine Product and Chronic or Other Types of Urticaria: Nationwide Registry-Based Cohort Study in Denmark

(332) Background Rates of Neuroinflammatory Disorders and Atrial Fibrillation – Conditions of Interest for Vaccine Safety Studies

(333) Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in South Korea

(333) Case Series Analysis of Immune-Mediated Neurological Events in Vaccinees following AZD1222 (ChAdOx1 nCoV-19): Results from a UK Post-authorisation Active Surveillance Study

(334) Characterization of COVID-19 vaccine data in the Sentinel System

(334) Comparative Seroprevalence Analysis of COVID-19 Vaccination Strategies: Insights from a Multicenter Study in Castilla-Leon, Spain

(335) COVID-19 and influenza vaccine co-administration among older U.S. adults

(336) Comparing disparities in uptake of COVID-19 and influenza vaccination among pregnant women, September 2020 and March 2022: English and Welsh national cohorts

(336) Current Approaches in Post-Approval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published Literature

(337) Comparison of Influenza and COVID-19 Vaccine Coverage Rates by Age in Selected Geographies During the 2022-2023 Season

(337) Defining a Post-vaccine Myocarditis Cohort by Applying CDC Case Definition to Structured EHR and Claims Data as a Proxy for Case Adjudication

(338) Cumulative Rates of Serious and Adverse Events of Special Interest in Vaccinees Following AZD1222 (ChAdOx1 nCoV-19): Results from a UK Post-authorisation Active Surveillance Study

(338) Effectiveness Evaluation of the Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey for Healthcare Professionals and Vaccinees

(339) Data mining for adverse events of influenza vaccine in children using a tree-temporal scan statistic analysis

(339) Eighteen-month follow-up cohort study of post-vaccination COVID-19 myocarditis in France compared with other forms of myocarditis

(340) Differences in self-reported adverse events after the first mRNA COVID-19 vaccination between pregnant and non-pregnant women

(341) Early use of Moderna’s mRNA-1273.815 monovalent vaccine: a descriptive analysis of a US Claims database

(341) Evaluating impact of time-varying confounders in self-controlled risk interval analysis in a vaccine-safety cohort event monitoring-based simulation study

(342) Effectiveness of BNT162b2 and CoronaVac in individuals with multimorbidity: a territory-wide case-control study

(342) Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine

(343) Effectiveness of Maternal mRNA COVID-19 Vaccination Against COVID-19 Symptomatic Infection and Hospitalization in Infants Aged < 6 Months During the SARS-CoV-2 Omicron-Predominant Period: VENUS Study

(343) Healthcare utilization among SARS-CoV-2 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study

(344) Effectiveness Of Pertussis Vaccines In Children Between 2013 And 2019 In France: A Nested Matched Case Control Study Using The National Health Data System

(344) Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe

(345) Effectiveness of primary COVID-19 vaccination against severe infection in pediatrics: a cohort study using two linked data sources in Spain.

(345) Mapping Genetic and Molecular Contributions to Vaccine Adverse Reactions: a systematic review of observational studies

(346) Immunization Status of Rotavirus Vaccine among Infants in Korea

(346) Measuring Association of Acute Disseminated Encephalomyelitis and Transverse Myelitis following COVID-19 vaccination using a Self-Controlled Case Series Analysis of Real-World Linked Data

(347) Interim Utilization Results from a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States

(347) Methodological considerations for the design and implementation of real-world vaccine-related studies in low- and middle-income countries

(348) MotherToBaby Pregnancy Studies, Vaccines in Medications Surveillance System (VAMPSS) COVID-19 Vaccines Study

(348) Multimodal surveillance and the importance of enabling gender-based risk stratification capabilities in real world data

(349) Observed versus Expected Analysis of Adverse Events of Special Interest after AZD1222 (ChAdOx1 nCoV-19) Vaccination: Results from a UK Post-authorisation Active Surveillance Study

(349) Patient-level prognostic models for COVID-19 vaccine effectiveness and safety: a systematic review

(350) Pilot study on the application of rapid cycle analysis method for post-marketing active vaccine safety surveillance using COVID-19 vaccines in Japan: the VENUS Study

(351) Rates of SARS-CoV-2 Breakthrough Infection or Severe COVID-19 and Associated Risk Factors After Primary and Booster Vaccination Against COVID-19 in the Netherlands

(352) Quantifying Bias in COVID-19 Vaccine Effectiveness (VE) Estimates Due to Missing Information on Prior SARS-CoV-2 Infection: an Assessment Using Data from the European COVIDRIVE Study

(352) Safety of Ancestral Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years

(353) Rare adverse events of interest following vaccination: Strengths and weaknesses of a national data resource compared to the national sentinel network database

(353) Serious Neurological Adverse Reactions to SARS-CoV-2 Vaccines in Chile

(354) Real-world Nuvaxovid COVID-19 vaccine safety profile after first 100,000 doses in Australia

(354) Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis after COVID-19 Vaccination

(355) Relative effectiveness (rVE) of the high-dose vs. standard-dose influenza vaccines in the French National health data system (SNDS) for people aged 65+ living in community, obtained using two approaches based on the propensity score

(355) Tetanus, Diphtheria, Pertussis (Tdap) Vaccination During Pregnancy and Initiation of Human Milk Feeding

(356) Risk of Encephalitis and Meningitis After COVID-19 Vaccination in South Korea: a Self-controlled Case Series Analysis

(356) The Persistence in Risk and Effect Of COVID-19 Vaccination on Long-Term Health Consequences One Year After SARS-Cov-2 Infection: A Territory-Wide Cohort Study in Hong Kong

(357) Risks of Cardiovascular Events Following COVID-19 Vaccination – Results From a Nationwide Cohort Study of 8 Million Swedish Adults

(357) The Use of Background Incidence Rates to Support Vaccine Safety Monitoring: Challenges and Future Opportunities in the Framework of Beyond COVID Monitoring Excellence (BeCOME)

(358) Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States

(358) Use of test-negative designs in pharmacoepidemiology: focus on vaccine effectiveness 2013-2023

(359) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment

(360) Feasibility of Prospective Real-World Studies to Fulfill Regulatory Commitments and Requirements in Oncology within the United States (US)

(361) Sex Inequity in Access to Safe Vaccination: A Sex Disaggregated Comparative Analysis of Vaccine Safety Surveillance Reports and Social Media Vaccine-Related Health Mentions.

(362) Stroke Risk Following Receipt of High-Dose/Adjuvanted Influenza Vaccinations Among U.S. Adults Aged ≥65 Years; 2016-2019

(363) The Association between COVID-19 Vaccines and Menstrual Disorders: A Systematic Review.

(364) The Importance of Standardization in Observed-to-Expected Analysis: Using COVID-19 Vaccine Adverse Event as an Example.

(365) Tokenization and linkage of state vaccine registry data to improve determination of COVID-19 vaccination status in a large administrative claims database

(367) VAC4EU study to identify risk factors and characterize the clinical course of myocarditis/pericarditis following mRNA-1273 vaccination in four European countries: first descriptive analyses

(368) Vaccine Cohort Event Monitoring: Enhancement of Safety Data Collection